PeptideMark

Safety Profile

PT-141 Side Effects: Frequency & Severity

PT-141 (bremelanotide) is FDA approved for HSDD with a well-characterized side effect profile from Phase III trials.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Common side effects

4

  • Nausea

    40%

    Most common side effect; typically mild to moderate.

  • Flushing

    20%

    Facial flushing related to melanocortin activation.

  • Headache

    11%

    Usually mild.

  • Transient BP increase

    Small increase for ~12 hours after dose. Do not use in uncontrolled hypertension or CV disease.

Uncommon side effects

3

  • Vomiting

    More common at higher doses.

  • Injection site reactions

    Mild pain or erythema.

  • Skin hyperpigmentation

    Focal or generalized darkening in ~1% with repeated use.

Rare side effects

1

  • Priapism (males, off-label)

    Theoretical risk in male off-label use.

Contraindications

  • Uncontrolled hypertension
  • Known cardiovascular disease
  • Known hypersensitivity

Drug interactions

  • Naltrexone (oral) — reduced naltrexone effectiveness
  • Antihypertensives — PT-141 may counteract antihypertensive effect

Special populations

Not recommended in pregnancy or lactation. Limited elderly data.

Overall safety summary

PT-141 has a favorable risk-benefit profile for HSDD. The transient blood pressure increase is the most clinically relevant consideration and contraindicates use in uncontrolled hypertension.

PT-141 side effects: FAQ

Can PT-141 cause permanent skin darkening?

Focal hyperpigmentation occurs in ~1% of users with repeated dosing. It may persist after discontinuation but typically fades.

Back to PT-141 profileLegal statusResearch timeline